dapsone has been researched along with Glycogen Storage Disease Type I in 3 studies
Glycogen Storage Disease Type I: An autosomal recessive disease in which gene expression of glucose-6-phosphatase is absent, resulting in hypoglycemia due to lack of glucose production. Accumulation of glycogen in liver and kidney leads to organomegaly, particularly massive hepatomegaly. Increased concentrations of lactic acid and hyperlipidemia appear in the plasma. Clinical gout often appears in early childhood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the risk of hemolysis in subjects with glucose-6-phosphate dehydrogenase (G6PD) deficiency who were treated for acne vulgaris with either dapsone gel, 5% (dapsone gel), or vehicle gel." | 9.13 | Hematologic safety of dapsone gel, 5%, for topical treatment of acne vulgaris. ( Jarratt, M; Pariser, D; Piette, WW; Sheth, P; Taylor, S; Wilson, D, 2008) |
| "To evaluate the risk of hemolysis in subjects with glucose-6-phosphate dehydrogenase (G6PD) deficiency who were treated for acne vulgaris with either dapsone gel, 5% (dapsone gel), or vehicle gel." | 5.13 | Hematologic safety of dapsone gel, 5%, for topical treatment of acne vulgaris. ( Jarratt, M; Pariser, D; Piette, WW; Sheth, P; Taylor, S; Wilson, D, 2008) |
| "Topical dapsone gel 5% is indicated for the treatment of acne vulgaris and has been marketed since late 2008." | 3.76 | Is topical dapsone safe in glucose-6-phosphate dehydrogenase-deficient and sulfonamide-allergic patients? ( Webster, GF, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Piette, WW | 1 |
| Taylor, S | 1 |
| Pariser, D | 1 |
| Jarratt, M | 1 |
| Sheth, P | 1 |
| Wilson, D | 1 |
| Tiono, AB | 1 |
| Dicko, A | 1 |
| Ndububa, DA | 1 |
| Agbenyega, T | 1 |
| Pitmang, S | 1 |
| Awobusuyi, J | 1 |
| Pamba, A | 1 |
| Duparc, S | 1 |
| Goh, LE | 1 |
| Harrell, E | 1 |
| Carter, N | 1 |
| Ward, SA | 1 |
| Greenwood, B | 1 |
| Winstanley, PA | 1 |
| Webster, GF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| ACZ ACN 01. A Phase 4, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Cross-Over Study to Further Evaluate the Risk of Hematological Adverse Events in G6PD-Deficient Subjects With Acne Vulgaris Treated With ACZONE™ (Dapsone) Gel, 5%.[NCT00243542] | Phase 4 | 64 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for dapsone and Glycogen Storage Disease Type I
| Article | Year |
|---|---|
Hematologic safety of dapsone gel, 5%, for topical treatment of acne vulgaris.
Topics: Acne Vulgaris; Adolescent; Adult; Anemia, Hemolytic; Child; Cross-Over Studies; Dapsone; Dermatologi | 2008 |
Chlorproguanil-dapsone-artesunate versus chlorproguanil-dapsone: a randomized, double-blind, phase III trial in African children, adolescents, and adults with uncomplicated Plasmodium falciparum malaria.
Topics: Adolescent; Adult; Africa South of the Sahara; Animals; Antimalarials; Artemisinins; Artesunate; Chi | 2009 |
1 other study available for dapsone and Glycogen Storage Disease Type I
| Article | Year |
|---|---|
Is topical dapsone safe in glucose-6-phosphate dehydrogenase-deficient and sulfonamide-allergic patients?
Topics: Acne Vulgaris; Administration, Cutaneous; Clinical Trials as Topic; Dapsone; Dermatologic Agents; Dr | 2010 |